Regression of Papillary Thyroid Cancer during Nivolumab for Renal Cell Cancer.
Cancer
Immune checkpoint inhibitors
Nivolumab
Thyroid cancer
Journal
European thyroid journal
ISSN: 2235-0640
Titre abrégé: Eur Thyroid J
Pays: England
ID NLM: 101604579
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
13
08
2019
accepted:
21
01
2020
entrez:
12
6
2020
pubmed:
12
6
2020
medline:
12
6
2020
Statut:
ppublish
Résumé
Immune checkpoint inhibitors have been recently approved for cancer treatment. Nivolumab is a monoclonal antibody specific for programmed cell death-1 (PD-1) that modulates T-cell response. It was initially used for the treatment of malignant melanoma and then approved in other cancers, such as non-small cell lung cancer and clear cell renal cell carcinoma (ccRCC). So far, the activity of nivolumab in patients with thyroid malignancies has been reported in a single case of anaplastic thyroid cancer. Here, we report the case of a patient with ccRCC who developed a papillary thyroid carcinoma (PTC) under first-line sunitinib treatment. During nivolumab, the second-line treatment for ccRCC, we unexpectedly observed a complete regression of PTC.
Identifiants
pubmed: 32523892
doi: 10.1159/000506107
pii: etj-0009-0157
pmc: PMC7265713
doi:
Types de publication
Case Reports
Langues
eng
Pagination
157-161Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
J Clin Oncol. 2015 Jun 10;33(17):1974-82
pubmed: 25605845
Cancers (Basel). 2018 Dec 05;10(12):
pubmed: 30563160
J Clin Oncol. 1999 Aug;17(8):2530-40
pubmed: 10561319
J Endocrinol Invest. 2014 Jun;37(6):593-9
pubmed: 24789536
N Engl J Med. 2016 Sep 15;375(11):1054-67
pubmed: 27626519
Endocr Pathol. 2018 Dec;29(4):317-323
pubmed: 30121940
J Clin Endocrinol Metab. 2012 Apr;97(4):1134-45
pubmed: 22278420
Endocr Relat Cancer. 2017 Feb;24(2):97-106
pubmed: 28093480
Ann Surg Oncol. 2017 Jun;24(6):1533-1539
pubmed: 27873099
Oncologist. 2017 Oct;22(10):1149-1151
pubmed: 28778959
Surgery. 2018 Jan;163(1):130-136
pubmed: 29128181
Ann Surg Oncol. 2012 Jun;19(6):1887-96
pubmed: 22227921
J Pathol Transl Med. 2018 Jan;52(1):9-13
pubmed: 28994272
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Expert Rev Anticancer Ther. 2018 Feb;18(2):149-159
pubmed: 29241377
Clin Cancer Res. 2018 Jul 1;24(13):3059-3068
pubmed: 29615459
Int J Endocrinol. 2018 Jul 5;2018:1742951
pubmed: 30123257
Eur J Endocrinol. 2014 Sep;171(3):R91-9
pubmed: 24833135
Thyroid. 2017 Apr;27(4):537-545
pubmed: 27825291
Oncotarget. 2016 May 31;7(22):32318-28
pubmed: 27086918
Thyroid. 2018 Oct;28(10):1243-1251
pubmed: 30132401
J Endocrinol Invest. 2018 Jun;41(6):703-709
pubmed: 29230715
EBioMedicine. 2017 Apr;18:50-55
pubmed: 28363612
Future Oncol. 2015;11(9):1307-26
pubmed: 25798726
J Natl Cancer Inst. 2007 Jan 3;99(1):81-3
pubmed: 17202116